The FDA is holding its first public hearing on CBD, the cannabis extract that has quickly grown into a billion-dollar industry. High-dose products could be restricted and require a prescription, while low-dose products similar to the CBD oils currently on the market could be widely available.

The FDA is holding its first public hearing on CBD, the cannabis extract that has quickly grown into a billion-dollar industry. High-dose products could be restricted and require a prescription, while low-dose products similar to the CBD oils currently on the market could be widely available.: https://n.pr/2XhBFrR Read more... http://bit.ly/2WA2YR1